Top Markets
#1 ADO Protocol ADO Protocol +335.27%
#2 Islamic Coin Islamic Coin +155.40%
#3 GoPlus Security GoPlus Security +45.02%
#4 Starpower Starpower +35.19%
#5 GAIB AID GAIB AID +24.67%
#6 Casper Network Casper Network +14.74%
#7 Nockchain Nockchain +12.81%
#8 Power Protocol Power Protocol +11.88%
#9 o1.exchange o1.exchange +11.28%
#10 Status Status +10.86%
Coin of the day
ADO Protocol ADO Protocol
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Pozycja w akcjach #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Cena akcji
$0.4264
Ostatnia synchronizacja: 2022-09-14
Kapitalizacja rynkowa
$7.93M
Zmiana (1 dzień)
-16.44%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Caladrius Biosciences, Inc. (CLBS)

Kategoria

Healthcare
Zyski dla Caladrius Biosciences, Inc. (CLBS)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Caladrius Biosciences, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Caladrius Biosciences, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE